Wockhardt Ltd
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
- Market Cap ₹ 10,533 Cr.
- Current Price ₹ 687
- High / Low ₹ 687 / 213
- Stock P/E
- Book Value ₹ 117
- Dividend Yield 0.00 %
- ROCE -4.44 %
- ROE -23.0 %
- Face Value ₹ 5.00
Pros
- Debtor days have improved from 237 to 179 days.
- Company's working capital requirements have reduced from 155 days to 122 days
Cons
- Stock is trading at 5.86 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.33%
- The company has delivered a poor sales growth of -5.82% over past five years.
- Company has a low return on equity of -13.8% over last 3 years.
- Promoters have pledged 52.9% of their holding.
- Earnings include an other income of Rs.27.0 Cr.
- Company has high debtors of 179 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2,203 | 1,805 | 1,887 | 2,217 | 2,298 | 2,477 | 1,557 | 890 | 987 | 1,372 | 1,072 | 1,154 | |
2,168 | 1,780 | 1,879 | 2,091 | 2,153 | 2,154 | 1,619 | 1,023 | 1,125 | 1,150 | 1,002 | 1,190 | |
Operating Profit | 35 | 25 | 7 | 126 | 145 | 323 | -62 | -133 | -138 | 222 | 70 | -36 |
OPM % | 2% | 1% | 0% | 6% | 6% | 13% | -4% | -15% | -14% | 16% | 7% | -3% |
906 | 319 | 465 | 62 | 248 | 57 | 126 | 138 | 884 | 38 | -168 | 27 | |
Interest | 154 | 34 | 19 | 108 | 169 | 170 | 171 | 220 | 200 | 273 | 229 | 237 |
Depreciation | 81 | 96 | 103 | 99 | 106 | 106 | 120 | 173 | 184 | 171 | 186 | 176 |
Profit before tax | 706 | 215 | 350 | -20 | 119 | 104 | -227 | -389 | 362 | -184 | -513 | -422 |
Tax % | 12% | 8% | 5% | 143% | -15% | 34% | 64% | 41% | -64% | 24% | 9% | 0% |
623 | 199 | 332 | 8 | 137 | 69 | -82 | -231 | 593 | -140 | -466 | -422 | |
EPS in Rs | 43.70 | 13.92 | 23.19 | 0.58 | 9.54 | 4.77 | -5.69 | -16.05 | 41.18 | -9.72 | -32.34 | -27.51 |
Dividend Payout % | 9% | 55% | 66% | 0% | 81% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -4% |
5 Years: | -6% |
3 Years: | 5% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -77% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 15% |
3 Years: | 11% |
1 Year: | 192% |
Return on Equity | |
---|---|
10 Years: | 1% |
5 Years: | -3% |
3 Years: | -14% |
Last Year: | -23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 |
Reserves | 763 | 882 | 1,016 | 1,113 | 1,164 | 1,239 | 1,171 | 939 | 1,551 | 2,140 | 1,681 | 1,719 |
Preference Capital | 299 | 299 | 299 | 0 | 0 | 0 | 234 | 0 | 0 | 0 | 0 | 0 |
174 | 184 | 840 | 1,984 | 2,120 | 1,773 | 1,651 | 2,370 | 2,078 | 2,024 | 2,013 | 2,136 | |
2,175 | 2,271 | 2,238 | 1,431 | 1,230 | 1,318 | 1,660 | 1,395 | 1,211 | 1,562 | 966 | 936 | |
Total Liabilities | 3,167 | 3,391 | 4,149 | 4,584 | 4,569 | 4,386 | 4,538 | 4,760 | 4,895 | 5,798 | 4,732 | 4,868 |
937 | 1,033 | 1,005 | 1,402 | 1,465 | 1,423 | 1,614 | 2,044 | 1,684 | 1,828 | 1,625 | 1,449 | |
CWIP | 482 | 582 | 792 | 664 | 665 | 653 | 381 | 305 | 716 | 825 | 823 | 833 |
Investments | 308 | 308 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 |
1,441 | 1,469 | 2,054 | 2,221 | 2,142 | 2,013 | 2,245 | 2,113 | 2,198 | 2,848 | 1,987 | 2,289 | |
Total Assets | 3,167 | 3,391 | 4,149 | 4,584 | 4,569 | 4,386 | 4,538 | 4,760 | 4,895 | 5,798 | 4,732 | 4,868 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,429 | 131 | -53 | -363 | -235 | 119 | 58 | 222 | -563 | -93 | 71 | 188 | |
482 | -25 | 203 | -1,015 | 369 | 451 | 120 | -16 | 1,014 | -244 | -3 | -75 | |
-1,841 | -188 | 425 | 764 | -133 | -524 | -69 | -274 | -480 | 430 | -236 | 346 | |
Net Cash Flow | 70 | -81 | 575 | -614 | 1 | 46 | 109 | -69 | -29 | 93 | -168 | 459 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 34 | 50 | 41 | 45 | 54 | 118 | 236 | 385 | 353 | 344 | 188 | 179 |
Inventory Days | 186 | 221 | 240 | 216 | 206 | 141 | 195 | 367 | 305 | 297 | 330 | 254 |
Days Payable | 165 | 151 | 158 | 134 | 133 | 167 | 325 | 611 | 355 | 446 | 507 | 459 |
Cash Conversion Cycle | 55 | 120 | 123 | 126 | 127 | 92 | 105 | 141 | 303 | 194 | 11 | -26 |
Working Capital Days | -136 | -56 | -171 | 73 | 33 | 9 | 79 | 39 | 193 | 173 | 170 | 122 |
ROCE % | 34% | 18% | 20% | 3% | 9% | 9% | -2% | -5% | -8% | 2% | -1% | -4% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 1d
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1d
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Wockhardt Limited has informed regarding the press release dated June 28, 2024 titled "Globally renowned US body Clinical & Laboratory Standard Institute (CLSI) awards high …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Wockhardt Limited has informed the stock exchange regarding a press release dated June 28, 2024 titled "Successful use of investigational antibiotic Zaynich (Zidebactam/Cefepime -WCK 5222) …
- Shareholder Meeting / Postal Ballot-Outcome of AGM 1d
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Mar 2022TranscriptNotesPPT
Market Position
The Co. is amongst top 3 Indian generic companies in the UK and 6th Largest generic supplier in Ireland in Retail and Hospital channels.
Its Wepox is the leader in Erythropoetin market (market share =21%)and Methylcobalamin Brand is no. 1 with (Methycobal= 26.7% market share) {#https://www.bseindia.com/bseplus/AnnualReport/532300/73832532300.pdf#page=34 #}